Drug Profile
Eculizumab biosimilar - Samsung Bioepis
Alternative Names: AMT904; EPYSQLI; SB12 - Samsung BioepisLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Samsung Bioepis
- Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antihypertensives; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 08 Jun 2023 Pooled safety and efficacy data from a phase I and II trials in paroxysmal nocturnal hemoglobinuria presented at the 28th Congress of the European Hematology Association(EHA-2023)
- 31 Mar 2023 Preregistration for Paroxysmal nocturnal haemoglobinuria (In adults, In adolescents, In children) in European Union (IV)
- 10 Dec 2022 Efficacy and pharmacokinetics data from a phase III trial in Paroxysmal nocturnal haemoglobinuria presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-HEM-2022)